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Abstract
In response to peripheral nerve injury, Schwann cells adopt a migratory phenotype and modify the extracellular matrix to
make it permissive for cell migration and axonal re-growth. Uridine 59-triphosphate (UTP) and other nucleotides are released
during nerve injury and activate purinergic receptors expressed on the Schwann cell surface, but little is known about the
involvement of purine signalling in wound healing. We studied the effect of UTP on Schwannoma cell migration and wound
closure and the intracellular signaling pathways involved. We found that UTP treatment induced Schwannoma cell
migration through activation of P2Y2 receptors and through the increase of extracellular matrix metalloproteinase-2 (MMP-
2) activation and expression. Knockdown P2Y2 receptor or MMP-2 expression greatly reduced wound closure and MMP-2
activation induced by UTP. MMP-2 activation evoked by injury or UTP was also mediated by phosphorylation of all 3 major
mitogen-activated protein kinases (MAPKs): JNK, ERK1/2, and p38. Inhibition of these MAPK pathways decreased both MMP-
2 activation and cell migration. Interestingly, MAPK phosphorylation evoked by UTP exhibited a biphasic pattern, with an
early transient phosphorylation 5 min after treatment, and a late and sustained phosphorylation that appeared at 6 h and
lasted up to 24 h. Inhibition of MMP-2 activity selectively blocked the late, but not the transient, phase of MAPK activation.
These results suggest that MMP-2 activation and late MAPK phosphorylation are part of a positive feedback mechanism to
maintain the migratory phenotype for wound healing. In conclusion, our findings show that treatment with UTP stimulates
in vitro Schwannoma cell migration and wound repair through a MMP-2-dependent mechanism via P2Y2 receptors and
MAPK pathway activation.
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Introduction
Peripheral nerve injury initiates a sequence of events through
which macrophages and Schwann cells clear damaged axons and
potentiate axonal regeneration and nerve remyelination [1].
During Wallerian degeneration, de-differentiating Schwann cells
secrete growth factors and neurite-promoting factors to guide the
growing axon, as well as proteolytic enzymes to remodel
extracellular matrix (ECM) and facilitate cell migration [2,3,4,5]
One important class of proteases are matrix metalloproteinases
(MMPs), a large family of zinc- and calcium-dependent enzymes
that act on a wide number of extracellular and cell surface
receptors, ligands, and adhesion and structural proteins [6,7].
MMP upregulation has been linked to the pathogenesis of
peripheral nerve damage [8,9,10,11]. Specifically, MMP-2 and
MMP-9 have been involved in remodeling of the ECM during
nerve degeneration and regeneration [12,13,14,15]. MMP-2 and
MMP-9 are highly expressed after sciatic nerve injury: MMP-9
activity increases acutely at the site of injury some hours after
nerve crush, whereas MMP-2 activity is delayed but maintained
during nerve regeneration proximally and distally to the injury
site, suggesting that MMP-2 acts to facilitate axonal extension
along the nerve matrix [10]. In spinal cord injury, the same
pattern is observed: MMP-9 activity is highly increased 12 to
24 hours after injury to facilitate leukocyte infiltration while
MMP-2 increases its activity 5 to 14 days after injury to facilitate
nerve recovery and limit the formation of a glial scar [16,17,18]. In
Schwann cells, MMP-9 is required for insulin-like growth factor
(IGF) release and the subsequent activation of the MEK/ERK
pathway via IGF-1 and ErbB receptors [19]. MMP-9 also activates
the Akt/ERK pathway and promotes migration by binding to the
low-density lipoprotein receptor-related protein [20]. Taking into
account these findings, the modulation of MMP activity may be a
relevant target to enhance regeneration in demyelinating diseases
of the peripheral nervous system (PNS) [17].
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There is a growing body of evidence implicating purinergic P2Y
receptors in cell communication, migration, and wound repair in
response to injury in many cell types [21,22,23,24]. After injury,
nucleotides released from cells activate the purinergic receptor-
signaling pathway to mediate the response to injury [25].
Nucleotide binding to P2Y receptors, which are coupled to the
protein Gaq, activates phospholipase Cb (PLCb). PLCb cleaves
phosphatidylinositol 4,5-biphosphate (PIP2) to diacylglycerol
(DAG) and phosphoinositol tri-phosphate (IP3), resulting in the
release of intracellular Ca2+ from endoplasmic reticulum stores.
The increase in cytosolic Ca2+ induces a myriad of alterations in
the tyrosine phosphorylation of proteins ranging from adhesion
molecules to members of the mitogen- activated protein kinase
(MAPK) family [26,27]. MAPKs such as c-Jun N-terminal protein
kinase (JNK), extracellular signal-regulating kinase (ERK), and
p38 transduce extracellular signals into various cellular responses
such as proliferation, differentiation, and migration [28,29,30,31].
Accumulating evidence suggests that these MAPKs play a role in
the migration of various cell types [32,33,34,35].
Although the activation of P2Y purinergic receptors is known to
activate a MAPK signaling cascade, the role of the purinergic
signaling pathway in relation with Schwann cell migration and
wound repair has not yet been described. The present study aimed
to determine the effect of extracellular uridine 59-triphosphate
(UTP) on Schwannoma cell migration and wound repair and to
establish whether MMP-2 is involved in this effect. For the first
time, we report that UTP stimulates in vitro Schwannoma cell
migration and wound repair through a MMP-2-dependent
mechanism via P2Y2 receptors and MAPK pathway activation.
Materials and Methods
Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin,
streptomycin, and glutamine were purchased from PAA (Linz,
Austria). Donor bovine serum (DBS) was purchased from Gibco
(Rockville, MD, USA). Suramin, PBS, Hoechst 33342, trypan
blue, forskolin, pituitary extract, protease and phosphatase
inhibitor cocktails, SB203580, SP600125, U0126, and UTP were
purchased from Sigma–Aldrich (St Louis, MO, USA). GM6001
was purchased from Merck Millipore (Billerica, MA, USA). All
other reagents used were of analytical grade.
Schwann cell line cultures
The rat schwannoma cell line RT4-D6P2T was purchased from
the European Collection of Cell Cultures (#93011415; ECACC,
Salisbury, UK) and maintained in DMEM high glucose medium
supplemented with 2 mM L-glutamine, 50 U/mL penicillin,
50 mg/L streptomycin, and 10% (v/v) DBS. Cultures were
incubated in a 5% CO2 humidified atmosphere at 37uC. Cells
were seeded at a density of 1.26105 cells/cm2 and starved in 1%
(v/v) DBS for 24 h before nucleotide treatment.
Schwann cell primary cultures
Schwann cells were isolated from the sciatic nerves of Sprague–
Dawley rats on postnatal days 7 to 10 as previously described [36].
After chemical and mechanical dissociation, cells were cultured on
dishes in DMEM high glucose medium supplemented with 10%
(v/v) DBS, 5 mM forskolin, 20 mg/mL pituitary extract, 2 mM
glutamine, 100 U/mL penicillin and 50 mg/L streptomycin. To
eliminate fibroblasts, cells were replated on poly-L-lysine and
laminin-coated culture dishes or wells according to the Kreider
group [37]. In the resulting cultures, Schwann cells had a purity of
more than 83% (Hoechst and S100 immunoreactivity). Cells were
used for experiments at 7 to 10 days in culture.
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting
Schwann cells were washed with PBS (pH 7.4) and lysed in
buffer that contained 50 mM Tris–HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA, 1% (v/v) NP-40, and protease and phosphatase
inhibitors. The lysates were incubated on ice for 10 min and
sonicated. Protein concentrations were measured using the
Bradford method. Thereafter, 30 mg of cell lysate was denatured
with sample buffer [50 mM Tris–HCl, 2% (v/v) SDS, 100 mM
DTT, 10% (v/v) glycerol, pH 6.8], subjected to 10% SDS-PAGE,
and transferred onto Immobilon-P membranes (Merck Millipore).
The membranes were blocked for 1 h with 5% (w/v) dried
skimmed milk in TBS-T buffer [50 mM Tris, 150 mM NaCl,
100 mM KCl, and 0.1% (v/v) Tween-20, pH 7.4], and incubated
with the following primary antibodies: rabbit anti-phospho-
ERK1/2 (9101; Cell Signaling Technology, Beverly, MA, USA;
1:1000), rabbit anti-ERK1/2 (9102; Cell Signaling Technology;
1:1000), rabbit anti-phospho-JNK (9251; Cell Signaling Technol-
ogy; 1:1000), rabbit anti-JNK (9252; Cell Signaling Technology;
1:1000), rabbit anti-phospho-P38 (ab4822; Abcam; 1:1000), rabbit
anti-P38 (ab27986; Abcam; 1:1000), rabbit anti-P2Y2 (ab10270;
Abcam; 1:1000), rabbit anti-MMP-2 (ab37150; Abcam; 1:500),
and mouse anti-GAPDH (AM4300; Applied Biosystems, Carls-
bad, CA, USA; 1:20000). Antibody binding was detected with the
corresponding HRP-coupled secondary antibody (Calbiochem;
1:5000), and the bands were visualised using the Luminata Forte
detection system (Merck Millipore). The immunoreactive signals
were quantified using Image J software (National Institutes of
Health, USA).
Gelatin zymography
Conditioned culture medium was collected and centrifuged at
15,000 rpm for 5 min at 4uC. The cleared medium was
concentrated 10-fold using Centricon with a 10-kDa pore size
(Merck Millipore). Samples (20 mg protein) of Schwann cell-
conditioned media were then resolved on 10% SDS-PAGE gels
containing 0.1% (w/v) gelatin as the protease substrate. After
electrophoresis, gels were washed with 100 mM Tris-HCl (pH 7.5)
and 2.5% (v/v) Triton X-100 for 30 min and subsequently
incubated for 16 h at 37uC in digestion buffer containing 100 mM
Tris-HCl (pH 7.5), 5 mM CaCl2, and 200 mM NaCl. Bands
corresponding to activity were visualized by negative staining
using 0.25% (w/v) Coomassie Brilliant Blue R-250 (Bio-Rad, CA,
USA) for 6 hours followed by destaining for 30 min in a solution
of 10% (v/v) acetic acid and 25% (v/v) isopropanol. To quantify
the MMP-2 activity, the intensities of negative stained bands were
analyzed using Image J software (National Institutes of Health,
USA). MMP-2 activity was expressed as the active MMP-2
intensity per total MMP-2 intensity (pro-MMP-2 plus active
MMP-2).
Immunocytochemistry
Schwann cells cultured on coverslips were fixed with 4% (v/v)
paraformaldehyde and 4% (w/v) sucrose in PBS, permeabilized by
incubation for 20 min with methanol in a solution that comprised
PBS–Triton (0.2%; v/v), 0.5% (w/v) BSA, and 20 mM glycine,
and then labelled with Hoechst 33342 (1 mg/mL) for 1 h at 25uC
in the dark. For MMP-2 staining, coverslips were incubated for
4 h with mouse anti-MMP-2 (ab37150; Abcam; 1:500) and
fluorescent secondary antibody conjugated with Alexa Fluor
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(Invitrogen, 1:2000) for 1 h. Finally, coverslips were mounted with
the anti-fading medium Fluoromount (Sigma) and fluorescence
microscopic images were obtained using a laser confocal
microscope (Leica DM IRB, Wetzlar, Germany). The immuno-
fluorescence intensity was quantified using MetaMorphH Software
(Molecular Devices, LLC).
Gelatinase activity
Gelatinase activity was determined with in situ zymography
using DQ-Gelatin fluorescein conjugate as a substrate. Schwan-
noma cells cultured on coverslips were washed with 0.5 M Tris-
HCl (pH 7.6), 1.5 M NaCl, 50 mM CaCl2, and 2 mM NaN3.
Cells were then treated with DQ-Gelatin (100 mg/mL) at 37uC for
2 h (EnzCheck Gelatinase Assay, Molecular Probes, USA).
Finally, coverslips were mounted with the anti-fading medium
Fluoromount (Sigma) and fluorescence microscopy images were
obtained using a laser confocal microscope (Leica DM IRB). The
number of fluorescence spots in each cell was counted in different
regions and the results were expressed as number of positive
MMP-2 Schwann cells per area.
Wound -healing assay
Schwann cells were seeded at 2.56105 cells/cm2 and incubated
for 48 h to allow for the formation of a monolayer. A wound was
created in the monolayer with a 1000 mL pipette tip. The cells
were then washed with PBS (pH 7.4) and replaced with DMEM
high glucose medium supplemented with 2 mM L-glutamine,
50 U/mL penicillin, 50 mg/L streptomycin, and 1% (v/v) DBS.
Cultures were incubated in a 5% CO2 humidified atmosphere at
37uC. Images of 4 random fields along the wound were taken at
different times using a Nikon camera connected to a Nikon
inverted light microscope. Wound closure was quantified by
measuring the percentage of the occupied wound area at different
times using the TScratch v1.0 program (Matlab, Zurich,
Switzerland). The rate of migration (velocity) was expressed as
occupancy (%) per hour.
Migration assay
Schwann cell migration assays were performed using BD
BioCoat cell culture inserts with 6.5-mm-diameter filters with an
8-mm pore size according to the manufacturer’s instructions (BD
Biosciences). Schwann cells at a density of 1.56105 cells/insert
were seeded into the upper chamber in complete medium:
DMEM high glucose medium supplemented with 2 mM L-
glutamine, 50 U/mL penicillin, 50 mg/L streptomycin, and 1%
(v/v) DBS. Complete medium with UTP was placed in the lower
chamber as the chemoattractant. After incubation in a 5% CO2
humidified atmosphere at 37uC, the migrated cells in the lower
chamber were fixed with 70% (v/v) ethanol and stained with 0.2%
(w/v) Crystal Violet. For each membrane, the number of cells was
counted in 4 blindly chosen random fields under light microscopy.
The fold increase in cell migration was expressed by taking the
control value as 1.
Quantitative reverse transcription polymerase chain
reaction (RT-PCR)
The total RNA from 106 Schwann cells was isolated using
TRIzol reagent (Invitrogen, Paisley, UK) and reverse transcribed
using an iScript cDNA synthesis kit (Bio-Rad, Berkeley, CA,
USA). The cDNA template underwent quantitative analysis of
cDNA amplification, which was assessed using SYBR Green (Bio-
Rad). Standard PCRs were performed with the following specific
primers (100 mM each): MMP-2 (NM_031054), forward, 59-AGG
GAA TGA GTA CTG GGT CT-39, reverse, 59-CAG TTA AAG
GCA GCG TCTA C-39; P2Y2 receptor (NM_017255.1), forward,
59-CTG CCA GGC ACC CGT GCT CTA CTT-39, reverse, 59-
CTG AGG TCA AGT GAT CGG AAG GAG-39; P2Y4 receptor
(NM_031680.1), forward, 59-CAC CGA TAC CTG GGT ATC
TGC CAC-39, reverse, 59-CAG ACA GCA AAG ACA GTC
AGC ACC-39; P2Y6 receptor (NM_57124.1), forward, 59-GGA
GAC CTT GCC TGC CGC CTG GTA-39, reverse, 59-TAC
CAC GAC AGC CAT ACG GGC CGC-39; glyceraldehyde-3-
phosphate dehydrogenase, GAPDH (NM_017008.3), forward, 59-
TGG GAA GCT GGT CAT CAA C-39, reverse, 59-GCA TCA
CCC CAT TTG ATG TT-39. The NM number indicates the
accession number of each gene in the NCBI nucleotide database.
All amplified PCR products were verified by melting curve
analysis. Quantification was performed by the DDCT method, and
levels of mRNA expression were normalised to the housekeeping
gene that encodes GAPDH.
Short hairpin RNA
Knockdown Schwannoma cells were generated using short
hairpin RNA directed against the rat MMP-2 gene (shMMP-2)
constructed in the pLVTHM-GFP plasmid vector (Addgene,
Cambridge, USA). Sequence targeting for MMP-2 was selected
based on the rules for RNA susceptibility proposed by Tuschl’s
group [38] and using the siRNA prediction program from the
Whitehead Institute for Biomedical Research [39]. Two comple-
mentary DNA oligonucleotides (Roche, Berlin, Germany) were
annealed to produce a double-stranded DNA fragment encoding a
19-nucleotide sense strand, a 9-nucleotide loop, and a 19-
nucleotide antisense strand that correspond to bases 2173–2191
in MMP-2 mRNA (NM_031054). The sequence of MMP-2
shRNA is as follows: sense, 59-CGC GTC CCC GGA GAT ACA
ATG AAG TAA ATT AAG AGA TTT ACT TCA TTG TAT
CTC CTT TTT GGA AAT-39 and antisense, 59-CGA TTT
CCA AAA AGG AGA TAC AAT GAA GTA AAT CTC TTG
AAT TTA CTT CAT TGT ACT CCG GGG A-39. A plasmid
carrying a random sequence was used as a shRNA control
(shRandom). The sequence of the shRNA-Random is as follows:
sense, 59-GAT CCC CGC AGT GCA ATA TCG GAA ACT
TCA AGA GAG TTT CCG ATA TTG CAC TGC TTT TT-39
and antisense, 59-AGC TAA AAA GCA GTG CAA TAT CGG
AAA CTC TCT TGA AGT TTC CGA TAT TGC ACT GCG
GG-39. Duplex DNAs of shRNA-MMP-2 and shRNA-Random
were cloned into the ClaI and MluI sites of the pLVTHM vector.
The shRNA against P2Y2 was a generous gift from Dr. Dı´az-
Herna´ndez and Dr. Miras-Portugal (Universidad Complutense de
Madrid, Spain). RT4-D6P2T cells were transfected with different
shRNAs using Lipofectamine 2000 in accordance with the
manufacturer’s instructions (Invitrogen). Efficacy of shMMP-2
and shP2Y2 was tested in transiently transfected cells using
immunoblotting for the protein and quantitative RT-PCR for
mRNA expression (see Supporting Information, Fig. S1).
Statistical Analysis
Results were expressed as the mean 6SD of results from at least
3 independent experiments. Statistical analyses were carried out
using the GraphPad Prism 5.0 Software package (ANOVA
analysis plus Newman–Keuls post-test: *P#0.05, **P#0.01, and
***P#0.001).
Ethics Statement
Animal experimental procedures were submitted and autho-
rized by the Ethics Committee of the Universitat Internacional de
Catalunya (CEREA-UIC 2009).
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Results
UTP enhances Schwann cell migration and wound repair
In response to injury, Schwann cells increase their migration to
cover the damaged area. Previous studies on microglial, smooth
muscle, and epithelial cells have demonstrated that nucleotides
trigger wound repair [22,24,40]. To investigate the ability of the
nucleotide UTP to increase Schwannoma RT4-D6P2T cell
migration, dose–response and time–course studies were performed
using the Transwell migration assay (Fig. 1A). Dose–response
studies revealed that cell migration significantly increased after
UTP treatment (12 h, 100–500 mM). As previously reported, the
observed decrease in cell migration at 1 mM is due to UTP
cytotoxicity [41]. As extracellular concentration of UTP is greatly
enhanced after injury [42,43], a high UTP concentration
(250 mM) was used in all the experiments. On the other hand,
time–course analysis showed that cell migration significantly
increased between 6 and 12 h after UTP treatment (250 mM).
The effect of UTP on wound repair was also confirmed in
Schwann cell line and in primary cultured Schwann cells.
Treatment of these cells with UTP (250 mM) significantly reduced
the time required to close the wound completely (100%). RT4-
D6P2T cells incubated with UTP filled the wound after 20 hours
(Fig. 1B, d) compared to control cells, which occupied only
5668% of the wound area in that time (Fig. 1B, b). Likewise,
primary cultured Schwann cells treated with UTP filled the wound
after 36 hours (Fig. 1B, h), while untreated cells occupied only
57612% of the wound area in that time (Fig 1A, f). Quantitative
analysis of the wound–healing assay represented in Figure 1C
revealed that UTP treatment increases Schwann cell velocity 2.1-
fold (from 1.760.5% to 3.660.2% of occupancy/h) for primary
Schwann cells and a 1.6-fold increase (from 2.960.5% to
4.560.2% of occupancy/h) for the RT4-D6P2T cell line.
MMP-2 activation by UTP is essential for Schwann cell
wound repair
MMPs in their active form have the potential to promote cell
migration and are involved in wound repair [16]. In order to
determine whether UTP is able to induce MMP activation, the
activity of MMP-2 and MMP-9 in the conditioned media was
studied using gelatin zymography in RT4-D6P2T cells after UTP
treatment (250 mM). A time–response study revealed that MMP-2
becomes active (proteolytically cleaved) after 12 h to 24 h of UTP
treatment, whereas MMP-9 was not detected at any time during
the study (Fig. 2A). In the case of MMP-2, the pro-form of the
protein (67 kDa) showed similar levels in both controls and UTP-
conditioned media after 12 h to 24 h of incubation. By contrast,
the activity of the cleaved form of MMP-2 (60 kDa) appeared to be
clearly enhanced in UTP-conditioned medium (Fig. 2A). After
assessing UTP-induced MMP-2 activation in RT4-D6P2T cells,
we investigated whether MMP-2 activation was induced by
wound. Interestingly, gelatin zymography experiments showed
that MMP-2 was activated during wound healing (Fig. 2B), with
increased activation in the presence of UTP (250 mM, 12 h). This
amplified signal of the active form of MMP-2 was observed in the
Schwann cell line as well as the primary Schwann cell culture
(Fig. 2B). These results suggest that either the UTP nucleotide or
the conditioned medium from wounded cultures induce the
activation of MMP-2. The mRNA levels in RT4-D6P2T and
primary Schwann cells were also evaluated by quantitative RT-
PCR. Results showed that UTP significantly increases MMP-2
expression in both cell models after 6-24 hours of treatment (Fig.
S2).
Immunocytochemistry studies corroborated that MMP-2 pro-
tein expression is increased in primary Schwann cells (Fig. 2C, b)
treated with UTP (250 mM, 24 h) compared to control cells
(Fig. 2C, a). Quantitative analysis showed that the MMP-2
immunofluorescence intensity was significantly increased
(p = 0.018) in UTP-treated cells compared to untreated cells
(Fig. 2C). Furthermore, endpoint analysis of fluorescence-
quenched gelatin degradation in RT4-D6P2T cells revealed a
significant increase (p = 0.002) in the number of MMP-2 positive
cells in UTP-treated cells compared to untreated control cells
(Figure 2D). These findings are in agreement with the results
obtained by gelatin zymography and gene expression analysis and
corroborate that UTP enhances MMP-2 activation and expres-
sion.
Finally, to evaluate the role of activated MMP-2 in Schwan-
noma cell wound repair, a short hairpin RNA (shRNA) directed
against the rat MMP-2 gene (shMMP-2) was developed. Following
shMMP-2 transfection, substantial knockdown of the MMP-2
expression was observed in RT4-D6P2T cells at both mRNA
(81.360.2% decrease) and protein (52.360.7% decrease) levels
compared with transfected (shRandom) and nontransfected
control cells (see Supporting Information, Fig. S1). Wound healing
and zymography assays showed a significant decrease in the rate of
migration (P#0.001; Fig. 3A) and MMP-2 activation (P#0.05;
Fig. 3B) in MMP-2-silenced RT4-D6P2T cells when compared to
control cells. Altogether, these results strongly suggest that UTP-
activated MMP-2 plays an important role in Schwann cell wound
repair.
P2Y2 receptor is involved in Schwannoma cell wound
repair and MMP-2 activation
The expression of the uridine-sensitive P2Y receptors (P2Y2,
P2Y4 and P2Y6) was determined by RT-PCR in RT4-D6P2T cells
and in primary Schwann cell culture. As shown in Figure 4A, three
DNA fragments of 339, 377, and 450 bp were amplified. These
fragments matched the predicted sizes of the amplifications
products for the P2Y2, P2Y4 and P2Y6 receptor subtypes,
respectively. Given that P2Y2 receptor has been involved in cell
migration of several cell types, their implication in Schwann cell
wound repair was studied by using a shRNA directed against the
P2Y2 gene (shP2Y2). A significant decrease in the rate of migration
(P#0.001; Fig. 4B) and MMP-2 activity (P#0.01; Fig. 4C) in
P2Y2-silenced RT4-D6P2T cells was observed by wound healing
and zymography assays. This data suggest the involvement of
P2Y2 receptor in the UTP-induced Schwann cell migration and
MMP-2 activation.
To investigate whether the signaling pathway through P2Y
receptors is implicated in Schwannoma cell migration and MMP-2
activation, and given that P2Y receptors have been reported to
induce MAPK activity [25,44], we determined whether the P2Y-
MAPK pathway mediated UTP-induced migration in Schwann
cell line. RT4-D6P2T cells were pre-incubated for 20 min before
UTP (250 mM) stimulation with various selective inhibitors: a)
suramin, an antagonist at P2Y1, 2, 3, 6, 11 receptors [45,46]; b)
U0126, an inhibitor of MEK1/2 (upstream ERK1/2 kinase); c)
SB203580, an inhibitor of P38; d) SP600125, an inhibitor of JNK;
and e) the broad-spectrum MMP inhibitor GM6001. Results
revealed a significant decrease (P#0.001) in the rate of cell
migration (Figure 5A) and MMP-2 activation (Figure 5B) after
UTP treatment when cells were pre-incubated with 1 of the
inhibitors, in comparison with UTP-treated cells.
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Figure 1. UTP enhances Schwann cell migration and wound repair. (A) Transwell migration assay for RT4-D6P2T cells. Cells were seeded in
the upper side of a transwell membrane and treated with UTP (250 mM) at different times (2, 4, 6, 8, 10, and 12 h), or incubated for 12 h with various
UTP concentrations (0, 10, 100, 250, 500, and 1000 mM). Representative images (objective magnification610) of the dose–response and time–course
transwell migration studies are shown. Migrated cells were stained with crystal violet and counted. Data were expressed as the fold increases of cell
migration when compared to untreated cells. Values were calculated as the mean 6 SD using 3 independent experiments. Statistical significance:
*P#0.05, **P#0.01, and *** P#0.001. (B) Wound-healing assay for Schwann cell line and for primary Schwann cells. Monolayer cells for both Schwann
cultures were scraped (a, c, e, and g) and either untreated (b and f) or treated with 250 mM UTP (d and h). Micrographs are representative of at least 3
independent experiments (objective magnification 610). (C) Quantitative analysis of the rate of migration (velocity) calculated as percentage of
wound occupancy per hour. Values were calculated as the mean 6 SD of 3 independent experiments. Statistical significance: *** P#0.001.
doi:10.1371/journal.pone.0098998.g001
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UTP induces biphasic MAPK phosphorylation
To further study UTP stimulation of MAPKs, time–course
phosphorylation was investigated. RT4-D6P2T cells were treated
with UTP and cell lysates were collected after various time
intervals. Equal amounts of protein were resolved in SDS-PAGE
and blotted with MAPK antibodies against phospho-JNK,
phospho-ERK1/2, and phospho-P38. The same membranes were
also blotted with antibodies against total (active and non-active)
forms of MAPKs (JNK, ERK1/2 and P38). Stimulation of RT4-
D6P2T cells with UTP (250 mM) resulted in a transient increase in
all phosphorylated MAPK levels at 5 min (Fig. 6A: early
phosphorylation), which decreased to near baseline levels at
approximately 45 to 120 min after stimulation. A second wave of
increased phosphorylated MAPK levels appeared at approximate-
ly 6 to 12 h and was sustained for up to 24 h (Fig. 6A: late
phosphorylation). It was previously described that suramin was
able to block the early UTP-induced phosphorylation [47]. Our
data show that suramin pretreatment also blocked the late UTP-
induced late phosphorylation (Fig 6B). These results suggest that
UTP activates P2Y2 receptors, initiating downstream signaling
cascades and resulting in biphasic MAPK phosphorylation.
MMP-2 activation mediates late MAPK phosphorylation
To determine a possible relationship between MAPK phos-
phorylation and MMP-2 activation, MMP-2-silenced RT4-
D6P2T cells were treated with UTP (250 mM) and cell lysates
were collected at different times. Next, western blotting for 3
phosphorylated MAPKs was performed. Results showed that
while early phosphorylation is similar to that in control cells, late
MAPK phosphorylation is significantly downregulated in MMP-2-
silenced cells (Fig. 7A). To confirm the involvement of active
MMP-2 in late MAPK phosphorylation, RT4-D6P2T cells were
stimulated with UTP in the absence or presence of a broad-
spectrum MMP inhibitor (10 mM, GM6001) and MAPK phos-
phorylation levels were measured in cell extracts collected 5 min
(early phosphorylation; Fig. 7B) or 12 h (late phosphorylation;
Fig. 7C) after UTP treatment. GM6001 treatment did not inhibit
the early increase but significantly (P#0.05) reduced the UTP-
stimulated late increase in phosphorylated MAPK levels. These
results suggest that a UTP-induced late increase in MAPK
phosphorylation is MMP-2-dependent.
Discussion
Growing evidence suggests that nucleotides that are released
upon injury stimulate nucleotide P2 receptors and serve as
endogenous signals to induce a rapid wound healing response in
glial cells [48,49,50]. In analogy with other G-protein-coupled
receptors (GPCR), a cross-talk between P2Y and growth factor
receptors may occur at different levels of the signal transduction
Figure 2. UTP regulates MMP-2 activity and expression. (A) Time–course gelatin zymography analysis for Schwann cell line. Conditioned
media from 2.56106 RT4-D6P2T cells that were either treated or untreated with UTP (250 mM) at different times (6, 12, and 24 hours) were loaded on
SDS-PAGE gel containing gelatin. The zymogram is representative of 3 independent experiments. (B) Gelatin zymograms for a Schwann cell line and
primary Schwann cells after UTP and wound healing treatments. Conditioned media from Schwann cells were collected after 12 h of UTP (250 mM) or
wound healing treatments. Equal amounts of protein (20 mg) were loaded on SDS-PAGE gel containing gelatin. (C) Representative dual-fluorescence
labeling of MMP-2 (green) and nuclei (blue) using specific antibody against MMP-2 and Hoechst staining and quantitative analysis for primary
Schwann cells (a and b, objective magnification 640). Scale bar: 50 mm. Statistical significance: *P#0.05 compared to control cells. (D) In situ
zymography images and quantitative analysis of gelatinase activity in RT4-D6P2T cells. Scale bar: 50 mm. Statistical significance: **P#0.01 compared
to control cells.
doi:10.1371/journal.pone.0098998.g002
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pathway depending on receptor subtypes and the cell type and
their respective environments [51,52]. Extracellular nucleotides
are known to function as chemotactic agents for microglial cells,
smooth muscle cells, and epithelial cells [22,24,40,53]. However,
these studies did not explain the implication of the nucleotide
UTP, a selective P2Y agonist, in injured Schwann cells. We
hypothesize that UTP secreted to the medium during nerve injury
binds P2Y receptors in the neighboring Schwann cells to induce
MMP-2 activity and subsequent cell migration and wound
recovery.
In the PNS, MMP-2 activity has been shown to increase after
nerve injury and is associated with cell migration, axonal
outgrowth, nerve regeneration, and remyelination [14,17,54].
Our results demonstrate that cell migration and wound repair
significantly increased after UTP treatment in Schwann cells, and
that the velocity of these processes depends directly on MMP-2
activation. We have also described that UTP significantly increases
MMP-2 gene expression and that knockdown of MMP-2 is
Figure 3. UTP regulates MMP-2 activity. Wound healing and
gelatin zymograms of RT4-D6P2T cells transfected with shRNA directed
against the MMP-2 gene (shMMP-2) and control cells (non-transfected
cells or cells transfected with shRandom sequence). Representative
images (objective magnification 610) of wound healing and gelatin
zymograms and quantitative analysis of the rate of migration (velocity)
and MMP-2 activity are shown. Values were calculated as the mean 6
SD using 3 independent experiments. Statistical significance: *P#0.05
and ***P#0.001 when compared to control cells; #P#0.05 and
###P#0.001 when compared to UTP-treated cells.
doi:10.1371/journal.pone.0098998.g003 Figure 4. P2Y2 receptors are necessary for Schwann cell line
wound repair. (A) RT-PCR amplification with specific primers against
P2Y2, P2Y4, and P2Y6 receptor subtypes was performed in RT4-D6P2T
cells and in primary Schwann cells after the isolation of total RNA. PCR
products were separated on a 1% agarose gel and visualized with
ethidium bromide. (B-C) Wound healing and gelatin zymograms of
RT4-D6P2T cells transfected with shRNA directed against the P2Y2 gene
(shP2Y2) and control cells (non-transfected cells or cells transfected with
shRandom sequence). Representative images (objective magnification
610) of wound healing and gelatin zymograms and quantitative
analysis of the rate of migration (velocity) and MMP-2 activity are
shown. Values were calculated as the mean 6 SD using 3 independent
experiments. Statistical significance: **P#0.01 and ***P#0.001 when
compared to control cells; ##P#0.01 and ###P#0.001 when
compared to UTP-treated cells.
doi:10.1371/journal.pone.0098998.g004
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enough to completely suppress UTP-induced cell migration and
MMP-2 activation in the extracellular media.
Intracellular calcium measurements clearly indicate that UTP-
recognizing P2Y2 and P2Y4 receptors are functional in Schwann
cells [41]. Given that UTP is hydrolyzed by ectonucleotidases to
UDP, which is an agonist at P2Y6 receptor, we first identified the
P2Y receptor subtype that mediates Schwann cell migration and
MMP-2 activation. To that end, we used a pharmacological
approach (P2Y2 is suramin-sensitive) and P2Y2-knowdown of
Schwannoma cells, which suggested a predominant role of P2Y2
receptors in this migratory effect. Although UTP and ATP are
equivalent in stimulating P2Y2 receptor, we decided to study the
effect of UTP in order to avoid possible cross-signalling pathway
induced by the activation of P2X receptors by ATP [55]. Then,
our findings are consistent with previous reports demonstrating
that P2Y2 receptors are involved in cell migration in several cell
types, providing further evidence of the functional role of P2Y2
receptor during injury [56,57,58,59,60]. Indeed, P2Y2 receptors
have been shown to be upregulated in a variety of tissues in
response to injury [61]. All together, our data support the
hypothesis that activation of P2Y2 receptors by extracellular UTP
might regulate a reparative mechanism in response to wound
injury.
Our previous work, and that of other authors, showed that P2Y
receptor activation by UTP increases the expression of N-
cadherin, an adhesion molecule related to Schwann cell migration,
and that this increase is mediated by MAPK activation [47,62]. In
the present study, we also demonstrate that UTP-induced MMP-2
activation is dependent on MAPK signaling pathways. Indeed,
after nerve injury, increased activity in multiple pathways—
including the ERK/MAPK, JNK/c-Jun, Notch, and JAK/STAT
(Janus kinase/signal transducer and activator of transcription)
pathways—can be detected in Schwann cells [63,64]. Further-
more, some authors suggest that ERK and JNK activity defines
the state of Schwann cell differentiation. Whereas basal levels are
necessary for the differentiation of precursors, elevated ERK and
JNK activities drive dedifferentiation and migration [65,66,67,68].
By contrast, the role of p38 MAPK in Schwann cells is
controversial; it has been associated with the regulation of
myelination [69], but also with a negative regulatory role in
differentiation and myelination [70].
As previously described in many growth factors and cytokines,
UTP treatment also results in a biphasic phosphorylation of
MAPKs [71,72]. This kinetic profile has recently been proposed as
a model to allow a common signaling system to play distinct
regulatory roles depending on the temporal duration of activation
[73]. Although P2Y activation by UTP is well known to be
involved in early MAPK phosphorylation, the role of UTP in late
MAPK phosphorylation has not been described until now. Our
data suggests that the initial transient phase of MAPK activation in
Schwannoma cells is mediated by P2Y receptors [25,47], whereas
the late sustained phosphorylation is also mediated by MMP-2
activation. One possible explanation for late MAPK phosphory-
lation is that active MMP-2 in the extracellular space cleaves a
membrane-anchored growth factor on Schwannoma cells. Many
proteins released by proteolysis of the ECM proteins are known to
control cell response and may act as effectors for Schwann cell
migration [74]. Multiple lines of evidence indicate that growth
factors, such as neuregulin-1 (NRG1), are involved in Schwann
cell migration and myelination [75]. Furthermore, NRG1
expression and its putative receptors, ErbB2 and ErbB3, are
known to be induced in injured sciatic nerves in rats, promoting
Schwann cell proliferation and dedifferentiation in injured nerves
[76,77]. Thus, the cleavage of a growth factor (NRG1 type III) by
MMP-2 and the subsequent phosphorylation of the ErbB
transmembrane tyrosine kinase receptor could explain the late
MAPK phosphorylation observed in Schwannoma cells after UTP
treatment. This proposed hypothesis is based on previous
observations demonstrating that MMP-9 regulates MAPK path-
ways through IGF-1 and ErbB receptors [19]. Nevertheless,
the relationship between MMP-2 activation and late MAPK
Figure 5. P2Y2 receptors are necessary for Schwann cell line
wound repair. RT4-D6P2T cells were preincubated (30 min) with
selective inhibitors of different proteins involved in the P2Y receptor
signaling pathway: suramin (100 mM; P2Y2 receptor antagonist),
SP600125 (20 mM; JNK inhibitor), SB203580 (10 mM; P38 inhibitor),
U0126 (10 mM; ERK inhibitor), and GM6001 (10 mM; MMP inhibitor).
After UTP treatment (12 h, 250 mM), the rate of migration and MMP-2
activity were determined. Representative images are shown below the
corresponding graphs. Each bar represents the mean 6 SD using 3
independent experiments. Statistical significance: ***P#0.001 when
compared to UTP-treated cells.
doi:10.1371/journal.pone.0098998.g005
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Figure 6. UTP induces biphasic MAPK phosphorylation. (A) Western blot analysis of time–course MAPK phosphorylation induced by UTP. RT4-
D6P2T cells were incubated with UTP (250 mM) at the indicated times and equal amounts of protein (30 mg) were resolved in SDS-PAGE. Western
blots were performed using antibodies against phosphorylated and total MAPK (ERK1/2, JNK, and P38). The ratio of phosphorylated MAPK to total
MAPK was calculated by densitometry in each sample, and a value of 1 was given to the control cells. Representative western blots for each kinase
are shown above the graphs. Blots are representative of 3 independent experiments. Statistical significance: *P#0.05 compared to control cells. (B)
RT4-D6P2T cells were preincubated (30 min) with suramin (100 mM; P2Y2 receptor antagonist). After UTP treatment (12 h, 250 mM), the ratio of
phosphorylated MAPK to total MAPK was calculated by densitometry in each sample. Representative images are shown below the corresponding
graphs. Each bar represents the mean 6 SD using 3 independent experiments. Statistical significance: ***P#0.001 when compared to control cells;
##P#0.005, and ###P#0.001 when compared to UTP-treated cells.
doi:10.1371/journal.pone.0098998.g006
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Figure 7. MMP-2 activation mediates late MAPK phosphorylation. (A) Western blot analysis of time–course MAPK phosphorylation induced
by UTP. RT4-D6P2T cells transfected with shRNA against MMP-2 were incubated with UTP (250 mM) at the indicated times. (B-C) Schwannoma cells
were preincubated for 30 min with a broad-spectrum MMP inhibitor (GM6001, 10 mM) and then incubated with UTP (250 mM) at either 5 min (early
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phosphorylation observed in our Schwannoma cell model merits
further investigation in primary Schwann cell culture.
In light of these findings, we conclude that extracellular UTP
(which mimics nerve injury) stimulates Schwannoma cell migration
and wound repair through a MMP-2-dependent mechanism via
P2Y2 receptors and the activation of MAPK pathways. Moreover,
evidence that P2Y2 receptors mediate the migratory response of
Schwann cells evoked by PNS injury indicates that selective P2Y2
receptor agonists may provide new therapeutic opportunities for
Schwann cell migration and peripheral nerve regeneration.
Supporting Information
Figure S1 Short hairpin RNA validation. (A) RT4-D6P2T
cells were transfected with shRNA directed against a non-targeting
control (shRandom) or rat MMP-2 or P2Y2 genes, and after 48 h
MMP-2 and P2Y2 mRNA levels were determined by quantitative
RT-PCR. GAPDH was used as a constitutive gene. Statistical
significance: *P#0.05 compared to control cells. (B) RT4-D6P2T
cells were transfected with shRandom, shMMP-2 or shP2Y2, and
after 48 h MMP-2 and P2Y2 protein levels were determined by
immunoblotting. GAPDH was used as a constitutive protein.
(TIF)
Figure S2 Quantitative MMP-2 gene expression analy-
sis. Time–course MMP-2 gene expression analysis for Schwann
cell line (A) and for primary Schwann cells (B) treated or untreated
with UTP (250 mM). MMP-2 mRNA levels were determined by
quantitative RT-PCR. GAPDH was used as a constitutive gene.
Statistical significance: *P#0.05, **P#0.01, and *** P#0.001.
(TIF)
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